Four Biotechs Face Challenges Amid U.S. COVID-19 Vaccine Funding CutsFDAU.S. COVID-19 vaccine biotechs face funding cuts, regulatory changes, and operational challenges. Learn how Vaxart, Novavax, GeoVax, and CastleVax navigate this uncertain landscape impacting future pandemic preparedness.